Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Net Income (2016 - 2025)

Historic Net Income for Regen BioPharma (RGBP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.

  • Regen BioPharma's Net Income fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Dec 2025 it was -$759115.0, marking a year-over-year increase of 2691.72%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
  • Per Regen BioPharma's latest filing, its Net Income stood at -$572469.0 for Q3 2025, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's Net Income peaked at -$13047.0 during Q1 2021, and registered a low of -$572469.0 during Q3 2025.
  • Its 5-year average for Net Income is -$182475.5, with a median of -$128529.0 in 2022.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 8924.9% in 2021, then crashed by 81250.86% in 2022.
  • Regen BioPharma's Net Income (Quarter) stood at -$141432.0 in 2021, then plummeted by 240.25% to -$481226.0 in 2022, then skyrocketed by 69.88% to -$144932.0 in 2023, then tumbled by 255.6% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
  • Its last three reported values are -$572469.0 in Q3 2025, -$167292.0 for Q2 2025, and -$19354.0 during Q1 2025.